Cellphire Therapeutics is pioneering innovative hemostatic products aimed at revolutionizing bleeding treatment and enhancing patient outcomes. Their lead product, Thrombosomes® (FPH), is a freeze-dried platelet-derived hemostat designed to stabilize human cells for extended shelf life, allowing for rapid restoration and easy preparation. This technology addresses significant challenges associated with traditional liquid stored platelets, such as limited availability due to short shelf life and concerns regarding efficacy and safety. Additionally, Cellphire is developing Cryopreserved Platelets (CPP), which also aim to improve the availability of platelets for hospitals, particularly those with cold chain access. Both products are currently in Phase 2 clinical trials, with the potential to significantly impact trauma care and other medical applications.

In addition to their hemostatic products, Cellphire is exploring regenerative medicine applications, particularly for osteoarthritis, and has developed a method for high-resolution imaging of internal bleeding. Their regenerative medicine therapeutics aim to provide a consistent and effective alternative to current treatments, such as autologous platelet-rich plasma (PRP), which suffers from variability in composition. Furthermore, by utilizing the aggregation function of platelets, Cellphire has created a technology that enhances the concentration of contrast agents at bleeding sites, improving diagnostic capabilities and potentially reducing the need for invasive surgical interventions. Overall, Cellphire Therapeutics is committed to advancing cellular therapies that can save lives and improve the quality of care in various medical settings.

United States

Cellphire Therapeutics, Inc. is a Rockville, Maryland-based biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product, Thrombosomes®, a freeze-dried hemostatic agent derived from human platelets, is currently in a Phase I clinical trial. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine.

Cellphire Therapeutics

Company Details